15-min delayed · Jul 27, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 2 firms covering Ironwood Pharmaceuticals Inc, 1 rate it Buy or better, 1 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $5.00 to $10.00 (about 2.0x), a sign of real disagreement on valuation. The average target of $7.50 sits 92% above the current $3.92. The rating mix has held broadly steady over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.29 next quarter toward $1.44 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS2 ratings
Moderate Buy
Strong Buy00%
Buy150%
Hold150%
Sell00%
Strong Sell00%
Based on 2 analysts giving stock ratings to Ironwood Pharmaceuticals Inc.
As of Jul, 1 of 2 firms rate IRWD a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
IRWD EPS & revenue forecast
EPS · NEXT QUARTER
$0.29
Range $0.29 – $0.29 · 2 analysts · +21% YoY
Next period, 2 analysts expect Ironwood Pharmaceuticals Inc to earn $0.29 a share (range $0.29 – $0.29), versus $0.24 a year earlier. Full-year consensus is $1.09, growing to $1.44 the year after.
REVENUE · NEXT QUARTER
$119.5M
Range $115.0M – $122.2M · 2 analysts · -2% YoY
Revenue is expected to reach $119.5M (range $115.0M – $122.2M), -2.1% year-over-year. Full-year consensus is $460.1M, rising to $478.4M next year.
Top analysts covering Ironwood Pharmaceuticals Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on IRWD.
#1
Jason Butler
JMP Securities · Rank #22
Buy
$10.00+155.4% to target
Overall win rate
57%
+ Follow
#2
Chase Knickerbocker
Craig-Hallum · Rank #25
Buy
$8.00+104.3% to target
Overall win rate
58%
+ Follow
#3
Roy Buchanan
JMP Securities · Rank #109
Buy
$14.00+257.6% to target
Overall win rate
48%
+ Follow
#4
Mohit Bansal
Wells Fargo
Hold
$5.00+27.7% to target
Coverage
—
+ Follow
#5
JN
Jason N. Butler
Citizens
Buy
$10.00+155.4% to target
Coverage
—
+ Follow
IRWD stock forecast FAQ
What is IRWD's average 12-month price target?+
The 2 analysts with a live target average $7.50 for Ironwood Pharmaceuticals Inc over the next 12 months, ranging from a $10.00 high to a $5.00 low.
Is IRWD stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 2 analyst ratings, 1 are Buy or Strong Buy, 1 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for IRWD?+
The Street-high target is $10.00 (Citizens), and the Street-low is $5.00 (Wells Fargo). The average of all 2 active targets is $7.50.
How many Wall Street analysts cover IRWD?+
2 analysts have an active rating on Ironwood Pharmaceuticals Inc, and 2 firms carry a live 12-month price target.
Who is the most accurate analyst covering IRWD?+
Among analysts who currently cover IRWD, Jason Butler of JMP Securities has the strongest overall Quantellect track record (Rank #22). Their current call is Buy with a $10.00 target.
What is Ironwood Pharmaceuticals Inc's projected EPS for next quarter?+
The consensus estimate is $0.29 per share (range $0.29 – $0.29) across 2 analysts. Full-year EPS is projected at $1.09, rising to $1.44 the following year.
How much revenue is Ironwood Pharmaceuticals Inc expected to report next quarter?+
Consensus revenue is $119.5M (range $115.0M – $122.2M). Full-year revenue is projected at $460.1M, growing to $478.4M next year.
Have analysts been upgrading or downgrading IRWD lately?+
As of Jul, 1 of 2 firms rate IRWD a Buy (1 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their IRWD calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
